期刊文献+

硫酸氢氯吡格雷片人体相对生物利用度和生物等效性的评价 被引量:1

Relative bioavailability and bioequivalence of clopidogrel hydrogen sulfate tablets in healthy volunteers
下载PDF
导出
摘要 目的考察硫酸氢氯吡格雷片受试制剂和参比制剂的人体相对生物利用度,并评价两者的生物等效性。方法 32名健康男性志愿者随机交叉单剂量口服硫酸氢氯吡格雷片的受试制剂和参比制剂75mg,用LC-MS/MS法测定给药后血浆样本中氯吡格雷酸的浓度,用DAS软件计算其药代动力学参数,并评价两种制剂的相对生物利用度及生物等效性。结果测定人血浆中氯吡格雷酸的线性范围是10~7 000ng/mL,定量下限为10ng/mL;氯吡格雷酸和内标氯吡格雷酸-d4的平均提取回收率分别为88.1%和89.6%;批内、批间RSD均小于8.0%,RE在(±8.0%)以内。受试制剂和参比制剂的AUC0-t分别为(11 235.17±2 250.63)ng.h/mL和(10 835.07±1 994.46)ng.h-1.mL-1,AUC0-∞分别为(11 606.80±2 323.53)ng.h-1.mL-1和(11 201.94±1 953.69)ng.h-1.mL-1,Cmax分别为(4 724.07±1 399.60)ng/mL和(4 621.96±1 193.52)ng/mL,Tmax分别为(0.68±0.15)h和(0.70±0.23)h,t1/2分别为(8.21±3.26)h和(8.00±1.44)h。受试制剂的相对生物利用度F0-t和F0-∞分别为(103.7±9.6)%、(103.4±8.4)%。结论两种制剂的吸收速度和吸收程度相当,具有生物等效性。 Objective To evaluate the relative bioavailability and bioequivalence of two clopidogrel hydrogen sulfate tablets in healthy volunteers.Methods A single oral dose of 75 mg clopidogrel hydrogen sulfate test and reference tablets were given to 32 healthy male volunteers in a randomized,two-way crossway study.Clopidogrel acid concentrations in plasma were determined by LC-MS/MS.With use of DAS software,the pharmacokinetic parameters were calculated and the bioequivalence of the two preparations was evaluated.Results Clopidogrel acid was linear in the range of 10-7 000 ng/mL,with the lower of quantification of 10 ng/mL.The average recovery of clopidogrel acid and internal standard clopidogrel acid-d4 were 88.1% and 89.6%,respectively.Both intra-and inter-batch RSD were lower than 8.0%,and RE was within ±8.0%.The main pharmacokinetic parameters of test and reference preparations were as follows:AUC0-t(11 235.17±2 250.63) ng·h-1·mL-1 and(10 835.07±1 994.46) ng·h-1·mL-1,AUC0-∞(11 606.80±2 323.53) ng·h-1·mL-1 and(11 201.94±1 953.69) ng·h-1·mL-1,Cmax(4 724.07±1 399.60) ng/mL and(4 621.96±1 193.52) ng/mL,Tmax(0.68±0.15) h and(0.70±0.23) h;t1/2 were(8.21±3.26) h and(8.00±1.44) h,respectively.The F0-t and F0-∞ of test tablet were(103.7±9.6)% and(103.4±8.4)%,respectively.Conclusion The absorption rate and extent of the two preparations are comparative,and the two preparations are bioequivalent.
出处 《国际检验医学杂志》 CAS 2013年第10期1201-1202,1205,共3页 International Journal of Laboratory Medicine
关键词 硫酸氢氯吡格雷 氯吡格雷酸 生物利用度 生物等效性 clopidogrel hydrogen sulfate clopidogrel acid bioavailability bioequivalence
  • 相关文献

参考文献6

  • 1Close SL. Clopidogrel pharmacogenetics: metabolism and drug in- teractions[J]. Drug Metabol Drug Interact,2011,26(2) ..45-51.
  • 2Delavenne X, Basset T, Zufferey P, et al. Ultra-performance LC MS/MS method for quantification of elopidogrel active metabolite[J]. J Sep Sci,2010,33(13) :1968-1972.
  • 3Mullangi R, Srinivas NR. Clopidogrel review of bioanalytical methods, pharmaokinetics/pharmacodynamics, and update on recent trends in drug-drug interaction studies[J]. Biomed Chro- matogr, 2009,23 (1) .. 26-41.
  • 4李智,解华,田月洁.基因多态性与氯吡格雷的合理用药[J].中国药师,2010,13(12):1729-1733. 被引量:7
  • 5Mitakos A,Panderi I. A validated LC method for the determina- tion of clopidogrel in pharmaceutical preparations[J. J Pharm Bi- omed Anal,2002,28(34) :431-438.
  • 6Takahashi M, Pang H, Kawabata K, et al. Quantitative determina- tion o elopidogrel active metabolite in human plasma by LC-MS/ MS[J]. J Pharm Biomed Anal,2008,48(4).-1219-1224.

二级参考文献23

  • 1Kazui M, Nishiya Y, Ishizuka T, et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite[ J]. Drug Metab Dispos,2010, 38:92-99.
  • 2Brandt JT,Close SL,Iturria SJ,et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogre/ but not prasugrel[J]. J Thromb Haemost,2007,5:2429-2436.
  • 3Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel[ J]. N Engl J Med,2009,360:354-362.
  • 4Umemura K,Furuta T,Kondo K. The common gene variants of CYP2C19 affect pharmacokinetics and pharmacodynamics in an active metabolite of clopidogrel in healthy subjects[ J ]. J Thromb Haemost,2008,6:1439-1441.
  • 5Kim KA ,Park PW,Hong SJ,et al. The effect of CYP2C19 polymorphism on the pharmacokinetics and pharmacodynamics of clopidogrel : A possible mechanism for clopidogrel resistance[ J]. Clin Pharmacol Ther,2008,84:236-242.
  • 6Geisler T, Schaeffeler E, Dippon J, et al. CYP2C 19 and nongenetie factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation [ J ]. Pharmacogenomics ,2008,9 : 1251-1259.
  • 7Lee J M, Park S. , Shin DJ ,et al. Relation of genetic: polymorphisms in the cytochrome P450 gene wilh clopidogrel resistance after drug-elating stent implantation in Koreans [ J ]. Am J Cardiol,2009,104:46-51.
  • 8Shuldiner AR,O' Connell JR,Bliden KP,et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy[ J]. JAMA ,2009,302:849-857.
  • 9Taubert D, yon Beckerath N, Grimberg G, et al. Impact of P-glycoprotein on clopidogrel absorption [ J ]. Clin Pharmacol Ther,2006,80:486-501.
  • 10Sibbing D, Koch W, Gebhard D, et al. Cytochrome 2C19 * 17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement[ J ]. Circulation,2010,121 (4) :512-518.

共引文献6

同被引文献7

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部